A First Report of Radioembolization for Hepatic Metastases From Ocular Melanoma

Kennedy, Andrew S.; Nutting, Charles; Jakobs, Tobias; Cianni, Roberto; Notarianni, E.; Ofer, Amos; Beny, Alex; Dezarn, William A.

doi:10.1080/07357900802620893

Cited by 70 publications

(55 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The only available study included eleven uveal melanoma patients with metastases to the liver [555]. Seven patients (63 %) exhibited an objective response.…”

Section: Radioembolization/selective Internal Radiation Therapy (Sirt)mentioning

confidence: 99%

See 1 more Smart Citation

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

180

148

View full text Add to dashboard Cite

“…The only available study included eleven uveal melanoma patients with metastases to the liver [555]. Seven patients (63 %) exhibited an objective response.…”

Section: Radioembolization/selective Internal Radiation Therapy (Sirt)mentioning

confidence: 99%

“…Systematic search of the literature de-novo: [549][550][551][552][553][554][555][556][557][558][559][560][561][562][563][564][565][566] Strength of consensus: 100 %…”

Section: Level Of Evidencementioning

confidence: 99%

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

180

148

View full text Add to dashboard Cite

“…In the first study of 11 patients investigating the use of 90 Y SIR-Spheres to treat uveal melanoma, a response rate of 100% and a 1-year survival rate of 80% were reported for the 10 subjects who could be contacted for follow-up, with 1 patient experiencing a complete response at 3 months as assessed by PET/CT [21]. Since the original investigation [21], more recent studies have reported median disease progression-free and overall survivals ranging from 4.7 to 5.9 and from 7 to 12.3 months, respectively, among patients with uveal melanoma liver metastases treated with 90 Y microsphere radioembolization [22,23,24]. …”

Section: Discussionmentioning

confidence: 99%

Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases

et al. 2015

View full text Add to dashboard Cite

Aim: The aim of this study was to report a case of metastatic uveal melanoma in which radioembolized nodular liver metastases decreased in size while infiltrative sinusoidal metastases progressed, leading to jaundice without obstruction of the biliary ducts. Methods: The relevant clinical features, imaging, and histopathologic findings of this case are reviewed. Results: A 61-year-old Caucasian male with a history of uveal melanoma of the left eye status post plaque brachytherapy developed numerous liver metastases. After progression on systemic therapies, he underwent palliative radioembolization. Despite some radiographic improvement in the liver metastases, he developed hyperbilirubinemia without biliary tract obstruction or signs of liver failure. A biopsy of radiographically normal liver demonstrated extensive sinusoidal infiltration with melanoma. Conclusions: Distinct angiographic and histopathologic growth patterns of metastatic uveal melanoma differ in their amenability to radioembolization. Sinusoidal infiltration may lead to hyperbilirubinemia in the absence of overt obstruction or liver failure.

show abstract

“…While the experience is less for chemoembolization for neuroendocrine liver metastases, median progression-free survival (PFS) and overall survival (OS) of 18 and 69 months have been reported [Whitney et al 2011]. While less extensive, small studies have shown disease response in the majority of patients after chemoembolization [Fiorentini et al 2009a] and radioembolization [Kennedy et al 2009] for neuroendocrine liver metastases. IHP can provide significant benefit in patients whose disease is refractory to other therapies and who have limited treatment options.…”

Section: Introductionmentioning

confidence: 99%

Isolated hepatic perfusion for patients with liver metastases

2014

View full text Add to dashboard Cite

Up to 80% of colorectal, melanoma, and neuroendocrine liver metastases are unresectable due to excessive tumor burden. Isolated hepatic perfusion (IHP) administers intensive therapy to the liver while limiting systemic toxicity and thus may have an important role in the management of unresectable liver metastases. This review s describes the development of IHP, initial clinical results, open and percutaneous IHP techniques, and contemporary long-term treatment outcomes. IHP with melphalan or tumor necrosis factor α (TNFα) has been shown to achieve hepatic response rates of greater than 50% with progression-free survival of greater than 12 months among patients with refractory ocular melanoma liver metastases. The only series describing outcomes of IHP for neuroendocrine liver metastases notes an overall response rate of 50% and a median actuarial overall survival of 48 months after IHP treatment with melphalan or TNFα. The majority of studies that have evaluated IHP have been performed in patients with colorectal cancer liver metastases (CRCLM). In aggregate, survival results from retrospective studies and phase I/II clinical trials suggest that IHP demonstrated no significant survival benefit compared with systemic chemotherapy alone as first-line therapy. In contrast, IHP does improve outcomes relative to that provided by second-line chemotherapy for CRCLM, with overall response rates of 60% and median duration of liver response of 12 months. Continued evaluation of IHP for unresectable liver metastases is necessary to establish its role in multidisciplinary treatment approaches.

show abstract

A First Report of Radioembolization for Hepatic Metastases From Ocular Melanoma

Abstract: Radioembolization can control hepatic metastases of OM with very few side effects.

Cited by 70 publications

References 46 publications

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases

Isolated hepatic perfusion for patients with liver metastases

Contact Info

Product

Resources

About